Act Venture Capital

Few European venture firms can claim a continuous operating history through the dot-com bubble, the global financial crisis, the European sovereign debt episode and the post-2021 reset, but Act Venture Capital has run that gauntlet from the same Dublin office since 1994. Three decades of cycle exposure has made the firm visibly more disciplined than its peers about valuation, capital efficiency and the gap between product traction and durable enterprise revenue, and that posture now extends into an emerging healthcare and AI/ML book that has become the firm’s most active thesis area. With more than EUR 600 million raised across multiple funds and a sixth vehicle, ACT VI, recently closed at an initial EUR 140 million targeting roughly 35 companies, Act has positioned itself as the institutional anchor for ambitious technical founders building out of Ireland and the United Kingdom.

Act’s stated thesis centers on high-potential technology companies in artificial intelligence, machine learning, enterprise software, deep tech, healthcare and energy and climate. In healthcare specifically the firm has narrowed toward AI-enabled clinical software, with a clear preference for products that change the underlying economics of a clinical workflow rather than tools that sit beside it. The team has been explicit that it wants to back European founders who can compete globally from day one, and it underwrites accordingly: pricing discipline, early go-to-market validation in NHS or comparable European systems, and a credible path to US expansion are usually preconditions for a term sheet. The firm is not a conviction-on-faith investor; partners have publicly framed their model around capital efficiency and prefer companies that can demonstrate revenue traction before scaling team and burn.

The healthcare portfolio is anchored by Deciphex, the digital pathology software company that has emerged as a category leader in AI-accelerated pathology diagnostics. Act has framed Deciphex as a representative bet: a deeply technical European team building software that materially improves productivity and patient outcomes inside a regulated clinical workflow. The broader portfolio includes Cubic Telecom, the connectivity management platform, and Ekco, a managed cloud services provider, alongside additional positions across enterprise software and deep tech. For healthcare founders the relevant signal is that Act is one of the most active Series A and Series B investors in Irish and UK clinical software, and Deciphex’s progress through commercial deployment has given the team clear pattern recognition for what works inside hospital and pharma channels.

On stage and check size, Act invests across seed, Series A and Series B with stated check sizes in the USD 5 million to USD 25 million range. The firm typically leads or co-leads at Series A and is willing to anchor follow-on rounds out of the same fund. ACT VI’s 35-company target across an EUR 140 million initial close implies a deliberate strategy of concentrated bets with meaningful reserves, and the firm has been transparent that it expects to deploy multiple rounds of capital into its conviction positions. Founders raising pre-product seed rounds are generally a poor fit; Act prefers to enter at the point where there is product, early customers and a credible Series A narrative within the next 12 to 18 months.

The investment team is led by General Partner Conor Mills, with Principals Andrew O’Neill and Mairead Roche driving sourcing and diligence on healthcare and enterprise deals, and Associate Lorraine Paton supporting evaluation. The firm operates a relatively flat decision structure for a fund of its scale, and partner ownership of deals is the norm rather than committee-led sponsorship. Healthcare diligence typically routes through whichever principal owned the initial intake, with partner support brought in once technical and commercial validation is in place.

Warm introductions are the highest-conversion path. Act is deeply embedded in the Dublin technology ecosystem and has long relationships with Enterprise Ireland, NDRC and the major Irish university tech transfer offices, all of which serve as reliable referral channels. Existing portfolio founders, particularly those in Deciphex’s commercial network, are a strong second route. Cold outreach to Conor Mills or the principals via LinkedIn is read but rarely actioned without a credible referrer; founders are better served arriving with a clinical or commercial reference than with a warm-toned cold email.

What founders should know is that Act underwrites with the patience of a 30-year-old firm and the skepticism of one that has seen multiple cycles of European venture exuberance evaporate. Partners will push hard on capital efficiency, on European-to-US expansion sequencing, and on whether AI is actually the moat or merely the wrapper. Founders who arrive with a clear answer to those questions tend to find the process collaborative; those who do not will find it slow. For healthcare AI builders in Ireland and the UK, Act is among the most credible Series A leads in the region, and ACT VI’s deployment cadence makes the next 24 months a particularly relevant window.